Last updated: February 13, 2026
Overview:
NDC 76282-0714 corresponds to "Ocrevus" (ocrelizumab), a monoclonal antibody approved by the FDA for multiple sclerosis (MS) and primary progressive MS. Market dynamics are driven by disease prevalence, competitive landscape, regulatory factors, and payer coverage.
Market Size and Disease Demand
Multiple Sclerosis (MS) Prevalence:
- Estimated 2.8 million individuals globally with MS.
- US prevalence: approximately 900,000 cases (National Multiple Sclerosis Society, 2021).
- Ocrevus is approved for relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
Market Penetration:
- As of 2023, Ocrevus holds roughly 45% of the MS biologic market share in the US.
- Key competitors include Tecfidera, Kesimpta, and Mavenclad.
Treatment Volume Projections:
- US: Approximate baseline of 150,000 treated MS patients annually eligible for Ocrevus.
- Global: Estimated 250,000 patients receiving Ocrevus by 2025, considering expansion in Europe and Asia.
Pricing and Reimbursement Landscape
Pricing:
- Current wholesale acquisition cost (WAC) per 300 mg vial is approximately $6,000.
- Typical regimen: 600 mg (two vials) every six months, leading to annual gross drug cost of roughly $12,000 per patient.
- Actual net price varies due to negotiations, discounts, and rebates.
Reimbursement Factors:
- Payers have generally approved Ocrevus with favorable coverage.
- Patients' out-of-pocket costs are often between $0-$50 per infusion under insurance plans.
- Insurance coverage policies influence access and prescribing patterns.
Market Entry and Competitive Position
Regulatory and Market Trends:
- FDA approved Ocrevus in 2017.
- European Medicines Agency (EMA) approved in 2018.
- Manufacturers are expanding indications for PPMS, increasing volume potential.
Competitive Advantages:
- Ocrevus is the first approved single-agent therapy for both RRMS and PPMS.
- Efficacy and safety profile support sustained market share.
Challenges:
- High manufacturing costs for biologics.
- Biosimilar development may affect future pricing.
Price Projections (Next 3-5 Years)
Factors Influencing Price Trends:
- Market competition from biosimilars starting from 2024.
- Payer negotiations pushing for rebates and discounts.
- Potential for price erosion across biologics targeting MS.
| Year |
Expected Average Price per 300 mg Vial |
Notes |
| 2023 |
$6,000 |
Current market price |
| 2024 |
$5,800 |
Biosimilar entries, increased competition |
| 2025 |
$5,500 |
Broader biosimilar adoption, payer rebate pressure |
Revenue Implications:
- With approximately 150,000 treated patients in the US, revenue potential adjusts with price changes.
- US market revenues projected at ~$1.8 billion in 2023, declining to ~$1.65 billion by 2025 due to price erosion.
Key Risks and Opportunities
-
Risks:
- Patent expiration or biosimilar competition.
- Pricing pressures and reimbursement tightening.
- Development of more efficacious or convenient therapies.
-
Opportunities:
- Expanded indications for PPMS and other neurodegenerative diseases.
- Geographic expansion into emerging markets.
- Combination therapies with complementary mechanisms.
Summary
Ocrevus (NDC 76282-0714) remains a leading MS biologic with an estimated global treated patient base nearing 250,000. While current pricing hovers around $6,000 per vial, market pressures drive a gradual decline, with projections indicating a 3-4% yearly decrease over the next five years. The revenue outlook remains robust with potential for expansion due to broad approval and expanded indications, despite emerging biosimilars.
Key Takeaways
- Ocrevus holds approximately 45% of the US MS biologic market.
- Current gross annual treatment costs per patient are around $12,000.
- Price projections anticipate a decline to ~$5,500 per vial by 2025.
- Biosimilar competition will likely exert downward pricing pressure.
- The global MS treatment population could reach 250,000 patients by 2025.
FAQs
1. How does biosimilar competition impact Ocrevus pricing?
Biosimilars entering the market, beginning around 2024, are expected to prompt price reductions as manufacturers compete on price and reimbursement strategies.
2. What are the main factors influencing Ocrevus’s market share?
Efficacy, safety profile, payer coverage, ease of administration, and competing therapies shape market share dynamics.
3. How are treatment costs for patients affected?
Insurance plans generally restrict out-of-pocket costs to under $50 per infusion, but patient costs depend on coverage negotiations.
4. What are the key indications driving demand?
Ocrevus is approved for RRMS and PPMS, with expanded indications increasing the eligible patient population.
5. What future markets could influence Ocrevus’s growth?
Emerging markets in Europe, Asia, and Latin America, along with potential new indications, present growth opportunities.
References
- National Multiple Sclerosis Society. (2021). MS prevalence statistics.
- FDA approval documents for Ocrevus (2017).
- IQVIA, 2023. MS biologics market overview.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies.
- MarketWatch. (2023). Biologic drug price trends.
